Physician profile
Ralph Fong
NPI 1447290994
$3,403.58
in general payments reported to CMS, 2019-2025
31 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $546 · 2021: $426 · 2022: $281 · 2023: $119 · 2024: $250 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.32 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $960.41 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $385.69 | 2019-2023 | Wegovy |
| Abbvie INC. | $336.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.16 | 2019-2024 | Jardiance |
| Pfizer INC. | $238.59 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $137.41 | 2019-2020 | |
| Allergan, INC. | $97.74 | 2019-2020 | |
| Abbott Laboratories | $91.94 | 2019-2023 | Freestyle Libre 3 |
| Mannkind Corporation | $72.74 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $70.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.40 | 2019 | |
| Endo Pharmaceuticals INC. | $66.90 | 2019 | |
| Antares Pharma, INC. | $60.35 | 2019 | |
| Radius Health, INC. | $51.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.92 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $49.11 | 2019-2020 | |
| Corcept Therapeutics | $46.01 | 2022-2023 | Korlym |
| Shire North American Group INC | $41.34 | 2019 | |
| Companion Medical, INC. | $29.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.71 | 2025 | |
| Insulet Corporation | $25.52 | 2019 | |
| Exact Sciences Corporation | $24.88 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $23.79 | 2025 | Recorlev |
| Amag Pharmaceuticals, INC. | $22.54 | 2019 | |
| Dexcom, INC. | $21.30 | 2024 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $19.21 | 2021 | |
| Tandem Diabetes Care, INC. | $17.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.85 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.78 | 2019 | |
| Lilly USA, LLC | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Fong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.